Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV

Infection

Volumn 41, Issue 1, 2013, Pages 21-26

  Rivero Juarez, A ^a   Mira, J A ^b   Camacho, A ^a   Neukam, K ^b   Perez Camacho, I ^c   Caruz, A ^d   MacIas, J ^b   Torre Cisneros, J ^a   Pineda, J A ^b   Rivero, A ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^c HOSPITAL DE PONIENTE   (Spain)

^d UNIVERSITY OF JAÉN   (Spain)

Author keywords

End of treatment response; HCV; HIV; Risk factors; Viral relapse

Indexed keywords

ANTIRETROVIRUS AGENT; INTERLEUKIN 28B; LOW DENSITY LIPOPROTEIN RECEPTOR; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BODY MASS; CAUCASIAN; DRUG RESPONSE; FEMALE; GENDER; GENETIC ASSOCIATION; GENOTYPE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OBESITY; PREDICTION; PROSPECTIVE STUDY; RECURRENCE RISK; RISK FACTOR;

ADULT; ANTIVIRAL AGENTS; COINFECTION; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RECURRENCE; RIBAVIRIN; RISK FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84873744969     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-012-0352-4     Document Type: Article

References (31)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2011;345:41-52.
2. Operskalski EA, Kovacs A. HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr HIV/AIDS Rep. 2011;8:12-22.
3. Soriano V, Vispo E, Labarga P, Medrano J, Barreiro P. Viral hepatitis and HIV co-infection. Antivir Res. 2010;85:303-15.
4. Hadigan C, Kottilil S. Hepatitis C virus infection and coinfection with human immunodeficiency virus: challenges and advancements in management. JAMA. 2011;306:294-301.
5. Soriano V, Pérez-Olmeda M, Ríos P, Núñez M, García-Samaniego J, González-Lahoz J. Hepatitis C virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients. AIDS Res Hum Retroviruses. 2004;20:351-3.
6. Medrano J, Barreiro P, Resino S, et al. Rate and timing of hepatitis C virus relapse after a successful course of pegylated interferon plus ribavirin in HIV-infected and HIV-uninfected patients. Clin Infect Dis. 2009;49:1397-401.
7. Núñez M, Mariño A, Miralles C, et al. Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr. 2007;45:439-44.
8. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. AASLD practice guidelines. Hepatology. 2009;49:1335-74.
9. Centers for Disease Control and Prevention (CDC). Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years - United States, 2008. MMWR Recomm Rep. 2008;57:1-8.
10. Medrano J, Neukam K, Rallón N, et al. Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV. Clin Infect Dis. 2010;15:1209-16.
11. Shirakawa H, Matsumoto A, Joshita S, et al. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology. 2008;48:1753-60.
12. Cheng WS, Roberts SK, McCaughan G, et al. Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing. J Hepatol. 2010;53:616-23.
13. Shin SR, Sinn DH, Gwak GY, et al. Risk factors for relapse in chronic hepatitis C patients who have achieved end of treatment response. J Gastroenterol Hepatol. 2010;25:957-63.
14. Deschênes M, Bain VG, Lee SS, et al. Identifying HCV genotype 1 patients at risk of relapse. Eur J Gastroenterol Hepatol. 2010;22:546-51.
15. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351:451-9.
16. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-Infected patients: a randomized controlled trial. JAMA. 2004;292:2839-48.
17. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438-50.
18. Rodríguez-Torres M, Ríos-Bedoya CF, Ortiz-Lasanta G, et al. Weight affect relapse rates in latinos with genotype 2/3 chronic hepatitis C (CHC) treated with peg IFN alfa-2a (Pegasys) 180 mcg/week and 800 mg daily of ribavirin for 24 weeks. J Med Virol. 2008;80:1576-80.
19. Jacobson IM, Brown RS Jr, Freilich B, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology. 2007;46:971-81.
20. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2005;352:2609-17.
21. Jian Wu Y, Shu Chen L, Gui Qiang W. Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C. Liver Int. 2006;26:166-72.
22. Pineda JA, Caruz A, Rivero A, et al. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis. 2010;51:788-95.
23. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;139:120-9.
24. Wiegand J, Neumann K, Böhm S, et al. Prediction of relapse after peginterferon alfa-2b/ribavirin therapy in chronic HCV genotype 1 patients is dependent on minimal residual virema but not on il28b genotype. In: 46th annual meeting of the European Association for the Study of the Liver, Berlin, Germany, March 30-April 3 2011.
25. Pineda JA, Caruz A, Di Lello FA, et al. Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients. AIDS. 2011;25:1415-20.
26. Grebely J, Pham ST, Matthews GV, et al. Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection. Hepatology. 2012;55:1058-69.
27. van de Laar TJ, Molenkamp R, van den Berg C, et al. Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam. J Hepatol. 2009;51:667-74.
28. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195-206.
29. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405-16.
30. Dieterich D, Soriano V, Sherman K, et al. Telaprevir in combination with pegylated interferon-α-2a + ribavirin in HCV/HIV-co-infected patients: a 24-week treatment interim analysis. In: 19th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, USA, March 2012. Oral abstract 46.
31. Sulkowski M, Pol S, Cooper C, et al. Boceprevir + pegylated interferon + ribavirin for the treatment of HCV/HIV-co-infected patients: end of treatment (week 48) interim results. In: 19th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, USA, March 2012. Oral abstract 47.